Only over the last decade have we begun to understand the critical importance of microbes that are present within our localised environment. These communities of microbes, often referred to as microbiomes, can be advantageous or detrimental to human health.
There's a pressing need to discover or refine tools to enhance beneficial microbes within our local environments – and the removal of harmful microbes from these environments is also of critical importance.
Our experience and ongoing projects includes, but is not limited to:
- Discovery of novel antibacterial agents and high-throughput methods for rapid identification of such drugs (Draheim)
- Regulation of antibiotic entry into bacterial cells (Draheim)
- Discovery of novel antifungal agents (Lewis)
- Discovery of novel trypanocidal and leishmanicidal formulations (Lalatsa)
- Evaluation of antibacterial properties of silver nanospecies for tissue engineering applications (Roldo/Draheim)
- In vitro visualisation of biofilms and effects of oral care products (Roldo/Tozzi)
- The effects of antibacterial chemotherapy on intestinal microbiomal resistance (Fouch)
- The antibacterial and anti-adhesive properties of honey (Fouch)
- Industrial-related microbiology involving bio-corrosion and biochip design (Zinkevich)
One of the major challenges humanity faces right now is the increasing appearance of disease-causing microbes that we were able to control and which are now resistant to all available treatments. The end of the “golden era” of antibiotics means there is a major imminent threat to humanity from antibiotic resistance – and if we do not find effective new approaches to combat this threat, people will be again dying from infections that are currently treated with a course of antibiotics.
Additionally, our experience includes development of novel agents and formulations against bacteria, fungi and parasites. In addition, we also work with microbiomes that are beneficial to humans. This currently focuses on the microbial communities found within the human gut and those found coating the surface of human teeth.
Our research teams also have significant experience with microbes that directly affect human health or that affect the local environmental infrastructure that humans interact with.
Our research in microbiology covers the following topics
Drug design and discovery (new drugs)
Molecular signalling (understanding mechanisms of communication inside and between cells)
Synthetic microbiology (engineering bacteria for novel function)
Biomaterials and formulation (new man-made materials or reformulation of such materials)
Molecular modelling (aiding identification of new drugs and their properties even before these are made)
Ion channel biophysics (understanding drug targets)
Our research makes use of the following methods:
- Microbial growth (aerobic / anaerobic growth large volume and/or parallelised growth)
- Biochemical / Immunological methods (DNA/RNA/protein extraction, SDS-PAGE, protein purification, ELISA)
- Biophysical methods (fluorescence-based high-throughput screening)
- Synthetic microbiology (bacterial engineering and organ replication)
- Electrophysiology (high-throughput screening against fungal voltage-gated channels)
- Advanced imaging methods via the Zeiss Global Imaging Centre
We also have access to advanced imaging of biomaterials via the Zeiss Global Imaging Centre, and can conduct antibacterial testing of commercial materials. We also hold intellectual property (IP) for high-throughput screening for antimicrobial activity.
Funders and collaborations
We regularly collaborate on research with industry and academic partners around the world. We've worked on projects with Oxford Drug Design, UK; Huazhong Agricultural University, China; Wuhan HVSEN Biotechnology Co Ltd, China; GlaxoSmithKline Plc, UK; and Saudi Aramco, Saudi Arabia.
We've received research funding from major funders such as the UK's government-funded innovation agency Innovate UK, and the Chinese government's Ministry of Science and Technology.
Recent publication highlights
ACS Synth. Biol., 2017, 6 (7), pp 1315–1326, Roger R. Draheim, Christina E. Lehning, Jan B. Heidelberger, John Reinhard, Morten H. H. Nørholm
Potential Treatment Agent for Infectious Diseases? 25(7): 1-10, 2018; Article no.JAMMR.39349, Nouha Elmarbet , Mahmoud Ben Shaban, Basma Doro, Bashir A. Lwaleed, Sarah Fouch and Mohamed Elemam
Synthesis, Antibacterial Activity and Biomedical Applications, Appl. Sci. 2018, 8, 673; doi:10.3390/app8050673, Richard S. Jones, Roger R. Draheim, and Marta Roldo
Sources, Sinks and Solutions, Mar. Drugs 2017, 15, 158; doi:10.3390/md15060158, Joy E. M. Watts, Harold J. Schreier, Lauma Lanska and Michelle S. Hale
Discover our areas of expertise
We're looking at the architecture and function of the nervous system – and how it relates to development, normal health, and neurological disorders.
We're exploring the molecules and molecular processes that cause diseases, and working to develop better treatments.
We're investigating targeted drug delivery systems using nanoparticles, finding new ways to deliver active molecules in medicines to the right part of the body – at the right time, in the right amounts – and identifying drugs that can be 'repurposed' to treat other diseases.
Interested in a PhD in Pharmacy, Pharmacology & Biomedical Sciences?
Browse our postgraduate research degrees – including PhDs and MPhils – at our Pharmacy, Pharmacology & Biomedical Sciences postgraduate research degrees page.